Referred to the Committee on Energy and Commerce, and in addition to the Committees on Armed Services, Oversight and Government Reform, and Veterans' Affairs, for a period to be s…
The bill requires all health insurers and federal health programs to fully cover, with no cost-sharing, annual low-dose CT (LDCT) or other appropriate lung cancer screening for eligible adults aged 50–80 who a treating clinician determines are at increased risk for lung cancer. It forbids prior authorization, step therapy, annual frequency limits stricter than one screening per year, and documentation beyond recent evidence-based clinical guidelines.
Scope and role of federal mandates: liberals see removing cost and administrative barriers as pro-access; conservatives view mandates as federal overreach and a cost driver.
Relative to its intended legislative type, this bill clearly establishes a substantive coverage mandate to expand lung cancer screening and includes some administrative directions (actors subject to the mandate, prohibitions on certain utilization controls, a definition of eligible individuals, and a 180-day regulatory deadline).
The bill requires all health insurers and federal health programs to fully cover, with no cost-sharing, annual low-dose CT (LDCT) or other appropriate lung cancer screening for eligible adults aged 50–80 who a treating clinician determines are at increased risk for lung cancer.
It forbids prior authorization, step therapy, annual frequency limits stricter than one screening per year, and documentation beyond recent evidence-based clinical guidelines.
Federal agencies (HHS, Defense, VA, OPM) must issue implementing regulations within 180 days and ensure program-wide compliance.
On content alone this is a narrowly targeted preventive‑care mandate with clear implementing agency roles, which favors consideration and some bipartisan interest. However, mandatory no‑cost coverage across insurers and federal programs, elimination of prior authorization and cost‑sharing, and unspecified fiscal offsets introduce substantive cost and regulatory concerns that commonly slow or block enactment. The bill's short, implementable text helps, but payer opposition and budgetary questions reduce its chance of becoming law without amendment or incorporation into a larger package.
Relative to its intended legislative type, this bill clearly establishes a substantive coverage mandate to expand lung cancer screening and includes some administrative directions (actors subject to the mandate, prohibitions on certain utilization controls, a definition of eligible individuals, and a 180-day regulatory deadline). However, the bill leaves substantial operational detail to future regulation and omits expected elements such as fiscal acknowledgement, explicit integration with existing statutory provisions, concrete enforcement or remedies, reimbursement mechanics, and measurement/oversight provisions.
Scope and role of federal mandates: liberals see removing cost and administrative barriers as pro-access; conservatives view mandates as federal overreach and a cost driver.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and role of federal mandates: liberals see removing cost and administrative barriers as pro-access; conservatives view mandates as federal overreach and a cost driver.
This persona would generally view the bill positively as an expansion of preventive, evidence-based care that can reduce lung cancer mortality and improve health equity by removing cost and administrative barriers.
They will note the patient-centered risk determination and the ban on cost-sharing and prior authorizations as important to access, especially for lower-income and marginalized communities.
They will want assurances that the policy follows strong clinical evidence, pairs screening with smoking cessation and follow-up care, and includes outreach to underserved populations.
A centrist view would be cautiously supportive: preventive screening that reduces mortality is attractive, but they will want clarity on evidence alignment, fiscal impacts, and implementation mechanics.
They will appreciate the removal of administrative barriers but worry about unintended overuse, costs to insurers (and possible premium effects), and the need for monitoring and phased implementation.
They will prefer that the policy adhere closely to established evidence-based guidelines and include accountability measures.
This persona would be skeptical of a federal mandate requiring insurers to provide free annual screening and of prohibitions on utilization management tools.
While supportive of effective preventive care in principle, they would see this as federal overreach that imposes costs on private insurers, employers, and potentially taxpayers, especially because the bill lacks offsets or specific, narrow eligibility criteria.
They would also be concerned about government-driven guidelines overriding insurer oversight and about potential unnecessary procedures resulting from expanded screening.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone this is a narrowly targeted preventive‑care mandate with clear implementing agency roles, which favors consideration and some bipartisan interest. However, mandatory no‑cost coverage across insurers and federal programs, elimination of prior authorization and cost‑sharing, and unspecified fiscal offsets introduce substantive cost and regulatory concerns that commonly slow or block enactment. The bill's short, implementable text helps, but payer opposition and budgetary questions reduce its chance of becoming law without amendment or incorporation into a larger package.
The bill has not accumulated any surfaced votes yet.
Scope and role of federal mandates: liberals see removing cost and administrative barriers as pro-access; conservatives view mandates as fe…
On content alone this is a narrowly targeted preventive‑care mandate with clear implementing agency roles, which favors consideration and s…
Relative to its intended legislative type, this bill clearly establishes a substantive coverage mandate to expand lung cancer screening and includes some administrative directions (actors subject to the mandate, prohibi…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.